SG/PUT/BRISTOL-MYERS SQUIBB/60/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 01:15:50 15/06/2024 am IST | ||
| 1.77 EUR | +0.57% |
|
| Current month | -1.12% | ||
| 1 month | +24.65% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 14/24/14 | 1.77 | +0.57% |
| 13/24/13 | 1.76 | +7.32% |
| 12/24/12 | 1.64 | +1.23% |
| 11/24/11 | 1.62 | -2.41% |
| 10/24/10 | 1.66 | -5.14% |
Delayed Quote Deutsche Boerse AG
Last update June 15, 2024 at 01:15 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SV6QT3 |
| ISIN | DE000SV6QT30 |
| Date issued | 24/05/2023 |
| Strike | 60 $ |
| Maturity | 20/09/2024 (97 Days) |
| Parity | 10 : 1 |
| Emission price | 0.41 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.85 € |
|---|---|
| Lowest since issue | 0.31 € |
| Spread | 0.01 € |
| Spread % | 0.56% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.2
USD
Average target price
53.19
USD
Spread / Average Target
+29.11%
- Stock Market
- Warrants
- Warrant
